Evogene (EVGN)
NASDAQ:EVGN
EVGN Stock Chart & Stats
$1.10
-$0.12(-6.82%)
At close: 4:00 PM EST
$1.10
-$0.12(-6.82%)
Day’s Range― - ―
52-Week Range$0.73 - $2.42
Previous CloseN/A
Volume47.40K
Average Volume (3M)115.16K
Market Cap
$7.15M
Enterprise Value-$3.50M
Total Cash (Recent Filing)$12.99M
Total Debt (Recent Filing)$2.20M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
May 27, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding8,718,193
10 Day Avg. Volume235,429
30 Day Avg. Volume115,158
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-105.63
Price to Sales (P/S)2.25
P/FCF Ratio-0.64
Enterprise Value/Market Cap-0.49
Enterprise Value/Revenue-0.89
Enterprise Value/Gross Profit-6.61
Enterprise Value/Ebitda0.31
Forecast
1Y Price Target
$1.75Price Target Upside59.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.35
Revenue Forecast (FY)$2.15M
Bulls Say, Bears Say
Bulls Say
Cost ManagementCost controls have appropriately been implemented, leading to a lower than expected operating expense and an EBITDA beat despite lower revenues.
Potential GrowthCasterra is believed to be a potential catalyst for the stock via commercial successes, with material value also seen in AgPlenus and Lavie Bio.
Bears Say
Order DelaysDelays in current order delivery and a follow-on order continue to be a material headwind for investors.
Order VisibilityThere is little visibility of a follow-on order at Casterra, which was expected to be a significant commercial catalyst.
Stock DilutionThe diluted share base effectively doubled due to a $5.5M raise, contributing to the decision to lower the price target.
Evogene News
EVGN FAQ
What was Evogene’s price range in the past 12 months?
Evogene lowest stock price was $0.73 and its highest was $2.42 in the past 12 months.
What is Evogene’s market cap?
Evogene’s market cap is $7.15M.
When is Evogene’s upcoming earnings report date?
Evogene’s upcoming earnings report date is May 27, 2026 which is in 61 days.
How were Evogene’s earnings last quarter?
Evogene released its earnings results on Mar 05, 2026. The company reported -$0.609 earnings per share for the quarter, missing the consensus estimate of -$0.26 by -$0.349.
Is Evogene overvalued?
According to Wall Street analysts Evogene’s price is currently Undervalued.
Does Evogene pay dividends?
Evogene does not currently pay dividends.
What is Evogene’s EPS estimate?
Evogene’s EPS estimate is -0.27.
How many shares outstanding does Evogene have?
Evogene has 8,718,193 shares outstanding.
What happened to Evogene’s price movement after its last earnings report?
Evogene reported an EPS of -$0.609 in its last earnings report, missing expectations of -$0.26. Following the earnings report the stock price went down -6.205%.
Which hedge fund is a major shareholder of Evogene?
Currently, no hedge funds are holding shares in EVGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
EVGN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced mix of positive strategic and operational developments and significant near-term financial and operational challenges. Positives include a clear strategic refocus on ChemPass AI, strong technical milestones (38 billion-molecule foundation model, 90% design precision), new automation collaboration with Google Cloud, key partnerships (Bayer, Corteva) and material reductions in operating costs that improved annual operating and net losses substantially. Negatives include meaningful revenue declines (≈30% year-over-year and ≈80% in Q4), a large inventory impairment (~$2.2M) that drove higher cost of revenues, a sharp reduction in financing income (~85% year-over-year), a deteriorating Q4 operating/net loss profile, and modest cash balances reliant in part on one-time discontinued-operations proceeds and future collaboration or financing catalysts. Overall, the strategic and technical progress is offset by current top-line weakness and one-time impairment impacts, leading to a balanced view of prospects and risks.View all EVGN earnings summariesEVGN Stock 12 Month Forecast
Average Price Target
$1.75
▲(59.09% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.05% Mutual Funds
0.12% Other Institutional Investors
98.47% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---